Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial

The activity and mild toxicity profile of single-agent gemcitabine therapy in untreated (chemonaive) patients with non-small-cell lung cancer (NSCLC) is well documented. This phase II trial was conducted to determine the objective tumour response rate and toxicity profile of single-agent gemcitabine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooten, M Van, Traine, G, Cinat, G, Cazap, E, Comba, A Zori, Vicente, H, Sena, S, Nievas, O Rodriguez, Orlando, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374290/
https://www.ncbi.nlm.nih.gov/pubmed/10555756
http://dx.doi.org/10.1038/sj.bjc.6690774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374290/
https://www.ncbi.nlm.nih.gov/pubmed/10555756
http://dx.doi.org/10.1038/sj.bjc.6690774

Ejemplares similares